Clinical Trials Logo
  1. Home
  2. Urogenital Neoplasms
  3. NCT04060628
  4. Details
NCT04060628 Clinical Trial

Expanded Access to NanoDoce

Urogenital Neoplasms Clinical Trial

Official title:
Expanded Access to NanoDoce

Clinical Trial Details — Status: Available

Administrative data
NCT number NCT04060628
Other study ID # NANODOCE-EA
Secondary ID
Status Available
Phase
First received
Last updated

Study information
Verified date November 2023
Source NanOlogy, LLC
Contact Gere diZerega, MD
Phone 805-595-1300
Email gere.dizerega@usbiotest.com
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Recruitment information / eligibility
Status Available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
NanOlogy, LLC US Biotest, Inc.
See also
  Status Clinical Trial Phase
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT04462926 - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed N/A
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Recruiting NCT04923178 - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Not yet recruiting NCT05030077 - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Phase 2
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Completed NCT01523652 - Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients N/A
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Terminated NCT02386111 - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04644432 - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT04811846 - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood N/A
Completed NCT04435964 - Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment
Recruiting NCT04922047 - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) Phase 1/Phase 2
Terminated NCT01918605 - Protection of Rectum From High Radiation Doses Using a Spacer N/A
Completed NCT01316458 - Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy Phase 2